Abbott, Dexcom, Insulet, Medtronic and others are developing next-gen sensors, pumps and algorithms for type 2 diabetes ...

EXEL announced that the FDA has approved the label expansion of its lead drug Cabometyx (cabozantinib). The regulatory body approved Cabometyx for the treatment of adult and pediatric patients 12 ...

Sometimes we have to laugh at the so-called health organizations in their plight to make us healthy. I think their intentions ...

Exelixis (EXEL) on Wednesday announced that the Food and Drug Administration has approved cabozantinib, or Cabometyx, for the ...

With 'For Melancholy Brunettes (and Sad Women),' the singer-songwriter explores the nuances of sorrow—just like the greats ...

In the latest installment of Healio’s video series with ASGE, Fiyinfoluwa O. Abraham, MD, discusses ethnic and racial disparities observed in the incidence of pancreatic cancer, demonstrating the need ...

Approval was based on findings from the pivotal CABINET trial showing improved PFS and response rates vs placebo.

Shares of Exelixis, Inc. EXEL have risen 13.3% year to date compared with the industry’s growth of 6.6%. The stock has also ...

After canceling a planned advisory committee meeting, the FDA has approved Exelixis’ Cabometyx for neuroendocrine tumors. | ...

The FDA has approved Cabometyx for some patients 12 years old and older with pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors.

The FDA approved cabozantinib for previously treated, unresectable, locally advanced or metastatic, well-differentiated ...

Actuate Therapeutics' elraglusib shows promise for pancreatic cancer, but financial instability and risks make it a high-risk ...